WASHINGTON — A trio of pharmaceutical manufacturers on Friday filed suit to overturn one of the most impactful drug pricing policies the Trump administration has enacted to date: a requirement that the companies include a medicine’s list price in direct-to-consumer advertising.

The drug makers — Amgen (AMGN), Merck, and Eli Lilly — were joined by the Association of National Advertisers on the lawsuit. In a press release, Amgen said the rule raises “freedom of speech concerns” and that it “fails to account for differences among insurance, treatments, and patients themselves.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Actually, I think that requiring manufacturers to advertise the price of their product can only lead to price-fixing and reduced competition. In fact, the so-called Manufacturer’s Suggested Retail Price was either outlawed or struck down in court something like 50 years ago. What might be sensible would be for the pharmacies to make it easier to determine prices. This whole thing is gnarly because of the drug benefit management business. Maybe that should be broken up.

  • It’s hard to see the “free speech” argument being successful.

    It’s settled law that the government can place requirements for commercial speech that would be unacceptable for non-commercial speech.

    For decades there’s been a federal requirement for nutrition labels on packaged foods and it hasn’t been struck down. There are federal rules on the use of terms like “organic” in commercial trade. There are federal regulations that require labeling of drugs in certain ways. The list of “federally compelled commercial speech” is very long and well established.

    States have all sorts of requirements that require pricing to be displayed. In my state, prices must be displayed on the shelf and/or on each item in a supermarket. There are also quite precise requirements on where and how gasoline prices must be displayed at gas stations (for example, visible from all streets on which there is an entrance to the station). Rules such as this have been in place for decades.

    The First Amendment has long since been “incorporated” onto state and local governments as well as, of course, applying to the federal government. Surely somewhere these disclosure rules would have been challenged successfully over the past decades if they were, in fact, in violation of the First Amendment.

    The argument that the average consumer doesn’t pay list price for drugs is a non-starter. If I’m a member of a gasoline discount group, I don’t pay list at the pump, but all the signs show the “list price” — that which anyone can buy the fuel without any negotiating or membership in some group. That’s just what “list price” is for drugs — the price that they will be sold to a buyer without negotiation or a special relationship.

  • Lawsuits prove its working. Big pharma is scared. Tip of the cap to the administration and HHS for actually trying to do something about the exploitative prices charged to American patients and taxpayers.

  • What are they all so afraid of? Besides, those of us with high deductibles pay list price and pbms and plan sponsors receive rebates on a good number of drugs, which can be around 50% of list. These monies are taken from the sick and presumably used to subsidize premiums for the healthy. Some unexpected rebates are kept as profit. Last year, rebates (also called the gross-to-net bubble) amounted to about $150-180B. List prices also drive up premiums, which insureds pay directly and indirectly. People who are only concerned about out-of-pocket don’t understand our opaque, convoluted system. Who can blame them?

  • I find really frivolous to sue over a policy that will do pretty much nothing in terms of prices reduction. At most, some temporary public outrage.
    I guess, they want just to remind everyone who is in charge

  • People are only concerned about what their out of pocket expense will be.
    Does anybody really care what the suggested retail price is ? It will confuse the
    average person and really has no value.

    • Jeff has it right. Outrage over something patients will never pay is purely a politically-motivated move heading into election season. A $2M gene therapy cure has no more bearing on a co-pay for that or any drug, than a given pro baseball player’s $100M multi-year pay package has on ticket prices, and fans don’t seem outraged at paying this for entertainment, much less their own or a loved one’s health. The debate in the US should be about the viability of health care being dependent on one’s employer and employment status.

  • so the drug makers are admitting that they screw the drug companies and somehow we dont care. geez .The prices for insurance is horrible ..but dont worry .

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy